Illumina Inc. has officially announced the spin-off of its cancer test subsidiary, Grail. The board of directors approved the spin-off, marking the end of a nearly four-year-long saga. As part of the divestment, Illumina will issue Grail shares to its investors while retaining a 14.5 percent stake in the company. Additionally, the board declared a spin-off dividend of Grail shares. The spin-off is set to be completed in June.
Illumina to Spin Off Grail by Issuing Shares to Investors, Will Keep 14.5 Percent https://t.co/QYkvSKRjMA
Illumina said that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long saga will finally draw to a close. https://t.co/elBz6CwGzE
Illumina's board approves to spin off Grail in June https://t.co/ac430BLJOV https://t.co/oIAV0O2yOl
Illumina board agrees to spin off Grail, as divestment plans proceed https://t.co/t3SJFHTgH9 via @Jasonmmast for @statnews
$ILMN Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares https://t.co/USzYXPsMa6 #illumina
Illumina makes the Grail spin-off official: $ILMN https://t.co/GHfZpQP9Cg